Interferon Treatment for Patients With Chronic Hepatitis C and End Stage Renal Disease
Status:
Completed
Trial end date:
2007-01-01
Target enrollment:
Participant gender:
Summary
The treatment response with conventional interferon alpha alone in patients with end stage
renal disease and chronic hepatitis C is about 33-39%. However, the drop-out rate is
17-29.6%. Pegylated interferon alpha, a newly developed form of interferon with superior
pharmacokinetic profiles, has not been used to treatment these patients. We expect the better
treatment response treated with peginterferon alpha than conventional interferon. In
addition, we also observe the safety of the two drugs during the study. The goal of the study
is to compare the efficacy and safety of the two different treatment regimens in patients
with chronic hepatitis C and end stage renal disease.